Version 5.4
| Bos taurus Gene: PPP2CA | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Summary | |||||||||||||||||||||||
| InnateDB Gene | IDBG-645797.3 | ||||||||||||||||||||||
| Last Modified | 2014-10-13 [Report errors or provide feedback] | ||||||||||||||||||||||
| Gene Symbol | PPP2CA | ||||||||||||||||||||||
| Gene Name | Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform | ||||||||||||||||||||||
| Synonyms | |||||||||||||||||||||||
| Species | Bos taurus | ||||||||||||||||||||||
| Ensembl Gene | ENSBTAG00000000469 | ||||||||||||||||||||||
| Encoded Proteins |
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform
|
||||||||||||||||||||||
| Protein Structure | |||||||||||||||||||||||
| Useful resources | Stemformatics EHFPI ImmGen | ||||||||||||||||||||||
| Entrez Gene | |||||||||||||||||||||||
| Summary |
This gene does not have any Entrez summary - the following is the summary from its human ortholog ENSG00000113575:
This gene encodes the phosphatase 2A catalytic subunit. Protein phosphatase 2A is one of the four major Ser/Thr phosphatases, and it is implicated in the negative control of cell growth and division. It consists of a common heteromeric core enzyme, which is composed of a catalytic subunit and a constant regulatory subunit, that associates with a variety of regulatory subunits. This gene encodes an alpha isoform of the catalytic subunit. [provided by RefSeq, Jul 2008] |
||||||||||||||||||||||
| Gene Information | |||||||||||||||||||||||
| Type | Protein coding | ||||||||||||||||||||||
| Genomic Location | Chromosome 7:47425980-47450747 | ||||||||||||||||||||||
| Strand | Reverse strand | ||||||||||||||||||||||
| Band | |||||||||||||||||||||||
| Transcripts |
|
||||||||||||||||||||||
| Interactions | |||||||||||||||||||||||
| Number of Interactions |
This gene and/or its encoded proteins are associated with 5 experimentally validated interaction(s) in this database.
They are also associated with 194 interaction(s) predicted by orthology.
|
||||||||||||||||||||||
| Gene Ontology | |||||||||||||||||||||||
Molecular Function |
|
||||||||||||||||||||||
| Biological Process |
|
||||||||||||||||||||||
| Cellular Component |
|
||||||||||||||||||||||
| Orthologs | |||||||||||||||||||||||
|
Species
Homo sapiens
Mus musculus
|
Gene ID
Gene Order
|
||||||||||||||||||||||
| Pathways | |||||||||||||||||||||||
| NETPATH | |||||||||||||||||||||||
| REACTOME |
APC truncation mutants have impaired AXIN binding pathway
G2/M Transition pathway
Signaling by Wnt pathway
Signaling by WNT in cancer pathway
ERKs are inactivated pathway
S33 mutants of beta-catenin aren't phosphorylated pathway
Toll Like Receptor 2 (TLR2) Cascade pathway
Negative regulation of FGFR signaling pathway
Metabolism of carbohydrates pathway
TRIF-mediated TLR3/TLR4 signaling pathway
Mitotic G1-G1/S phases pathway
Spry regulation of FGF signaling pathway
Cyclin A/B1 associated events during G2/M transition pathway
Toll Like Receptor 3 (TLR3) Cascade pathway
Cyclin D associated events in G1 pathway
Signaling by GPCR pathway
DARPP-32 events pathway
Activated TLR4 signalling pathway
Toll Like Receptor 7/8 (TLR7/8) Cascade pathway
M Phase pathway
MyD88-independent cascade pathway
Costimulation by the CD28 family pathway
Toll Like Receptor 9 (TLR9) Cascade pathway
Separation of Sister Chromatids pathway
MyD88:Mal cascade initiated on plasma membrane pathway
G1/S Transition pathway
Toll Like Receptor 5 (TLR5) Cascade pathway
G1 Phase pathway
TCF dependent signaling in response to WNT pathway
Signaling by FGFR pathway
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) pathway
misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling pathway
S37 mutants of beta-catenin aren't phosphorylated pathway
deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling pathway
Mitotic Metaphase and Anaphase pathway
Myoclonic epilepsy of Lafora pathway
Mitotic Anaphase pathway
Gene Expression pathway
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex pathway
Immune System pathway
Cell Cycle, Mitotic pathway
Integration of energy metabolism pathway
MAP kinase activation in TLR cascade pathway
Mitotic G2-G2/M phases pathway
Initiation of Nuclear Envelope Reformation pathway
truncations of AMER1 destabilize the destruction complex pathway
AXIN mutants destabilize the destruction complex, activating WNT signaling pathway
E2F mediated regulation of DNA replication pathway
XAV939 inhibits tankyrase, stabilizing AXIN pathway
Beta-catenin phosphorylation cascade pathway
Inhibition of replication initiation of damaged DNA by RB1/E2F1 pathway
CTLA4 inhibitory signaling pathway
Toll-Like Receptors Cascades pathway
Cell Cycle pathway
Signal Transduction pathway
Nuclear Events (kinase and transcription factor activation) pathway
AXIN missense mutants destabilize the destruction complex pathway
Toll Like Receptor 10 (TLR10) Cascade pathway
Nuclear Envelope Reassembly pathway
misspliced GSK3beta mutants stabilize beta-catenin pathway
Toll Like Receptor TLR6:TLR2 Cascade pathway
disassembly of the destruction complex and recruitment of AXIN to the membrane pathway
Glycogen storage diseases pathway
NGF signalling via TRKA from the plasma membrane pathway
PP2A-mediated dephosphorylation of key metabolic factors pathway
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation pathway
TCF7L2 mutants don't bind CTBP pathway
Glucose metabolism pathway
Metabolism pathway
deletions in the AMER1 gene destabilize the destruction complex pathway
Signalling by NGF pathway
AMER1 mutants destabilize the destruction complex pathway
ERK/MAPK targets pathway
Resolution of Sister Chromatid Cohesion pathway
Adaptive Immune System pathway
RNF mutants show enhanced WNT signaling and proliferation pathway
Toll Like Receptor TLR1:TLR2 Cascade pathway
MyD88 dependent cascade initiated on endosome pathway
MAPK targets/ Nuclear events mediated by MAP kinases pathway
Opioid Signalling pathway
Nonsense-Mediated Decay (NMD) pathway
S45 mutants of beta-catenin aren't phosphorylated pathway
Mitotic Prometaphase pathway
Innate Immune System pathway
Glycolysis pathway
APC truncation mutants are not K63 polyubiquitinated pathway
Disease pathway
Signaling by FGFR in disease pathway
Degradation of beta-catenin by the destruction complex pathway
Toll Like Receptor 4 (TLR4) Cascade pathway
MyD88 cascade initiated on plasma membrane pathway
T41 mutants of beta-catenin aren't phosphorylated pathway
truncated APC mutants destabilize the destruction complex pathway
|
||||||||||||||||||||||
| KEGG | |||||||||||||||||||||||
| INOH | |||||||||||||||||||||||
| PID NCI | |||||||||||||||||||||||
| Pathway Predictions based on Human Orthology Data | |||||||||||||||||||||||
| NETPATH |
TGF_beta_Receptor pathway
Wnt pathway
IL3 pathway
Prolactin pathway
|
||||||||||||||||||||||
| REACTOME |
MASTL Facilitates Mitotic Progression pathway
Resolution of Sister Chromatid Cohesion pathway
Mitotic Prometaphase pathway
Initiation of Nuclear Envelope Reformation pathway
Separation of Sister Chromatids pathway
Inhibition of replication initiation of damaged DNA by RB1/E2F1 pathway
E2F mediated regulation of DNA replication pathway
Cyclin D associated events in G1 pathway
Cyclin A/B1 associated events during G2/M transition pathway
ERKs are inactivated pathway
ERK/MAPK targets pathway
MyD88-independent cascade pathway
Toll Like Receptor 3 (TLR3) Cascade pathway
MyD88:Mal cascade initiated on plasma membrane pathway
Toll Like Receptor TLR1:TLR2 Cascade pathway
Toll Like Receptor TLR6:TLR2 Cascade pathway
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation pathway
MyD88 dependent cascade initiated on endosome pathway
Toll Like Receptor 9 (TLR9) Cascade pathway
MyD88 cascade initiated on plasma membrane pathway
Toll Like Receptor 10 (TLR10) Cascade pathway
Toll Like Receptor 4 (TLR4) Cascade pathway
Toll Like Receptor 5 (TLR5) Cascade pathway
CTLA4 inhibitory signaling pathway
Costimulation by the CD28 family pathway
Platelet sensitization by LDL pathway
Platelet homeostasis pathway
DARPP-32 events pathway
Opioid Signalling pathway
Spry regulation of FGF signaling pathway
Negative regulation of FGFR signaling pathway
Signaling by FGFR pathway
Beta-catenin phosphorylation cascade pathway
Degradation of beta-catenin by the destruction complex pathway
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) pathway
Glycolysis pathway
PP2A-mediated dephosphorylation of key metabolic factors pathway
Integration of energy metabolism pathway
Signaling by FGFR in disease pathway
truncated APC mutants destabilize the destruction complex pathway
G1 Phase pathway
Signalling by NGF pathway
AXIN mutants destabilize the destruction complex, activating WNT signaling pathway
Toll Like Receptor 7/8 (TLR7/8) Cascade pathway
APC truncation mutants are not K63 polyubiquitinated pathway
AMER1 mutants destabilize the destruction complex pathway
Nonsense-Mediated Decay (NMD) pathway
misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling pathway
Signaling by WNT in cancer pathway
Myoclonic epilepsy of Lafora pathway
AXIN missense mutants destabilize the destruction complex pathway
Signaling by Wnt pathway
Mitotic G1-G1/S phases pathway
Metabolism of carbohydrates pathway
Signaling by GPCR pathway
Innate Immune System pathway
disassembly of the destruction complex and recruitment of AXIN to the membrane pathway
APC truncation mutants have impaired AXIN binding pathway
Toll Like Receptor 2 (TLR2) Cascade pathway
Toll-Like Receptors Cascades pathway
T41 mutants of beta-catenin aren't phosphorylated pathway
G1/S Transition pathway
Signal Transduction pathway
MAP kinase activation in TLR cascade pathway
misspliced GSK3beta mutants stabilize beta-catenin pathway
S45 mutants of beta-catenin aren't phosphorylated pathway
deletions in the AMER1 gene destabilize the destruction complex pathway
Cell Cycle pathway
Adaptive Immune System pathway
Immune System pathway
S33 mutants of beta-catenin aren't phosphorylated pathway
truncations of AMER1 destabilize the destruction complex pathway
M Phase pathway
Mitotic Anaphase pathway
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex pathway
TCF dependent signaling in response to WNT pathway
NGF signalling via TRKA from the plasma membrane pathway
G2/M Transition pathway
Mitotic Prophase pathway
Nuclear Envelope Reassembly pathway
deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling pathway
Cell Cycle, Mitotic pathway
RNF mutants show enhanced WNT signaling and proliferation pathway
TCF7L2 mutants don't bind CTBP pathway
Activated TLR4 signalling pathway
Nuclear Events (kinase and transcription factor activation) pathway
Mitotic G2-G2/M phases pathway
Metabolism pathway
MAPK targets/ Nuclear events mediated by MAP kinases pathway
XAV939 inhibits tankyrase, stabilizing AXIN pathway
TRIF-mediated TLR3/TLR4 signaling pathway
Gene Expression pathway
S37 mutants of beta-catenin aren't phosphorylated pathway
Disease pathway
Glucose metabolism pathway
Glycogen storage diseases pathway
Hemostasis pathway
Mitotic Metaphase and Anaphase pathway
Toll Like Receptor 3 (TLR3) Cascade pathway
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation pathway
Toll Like Receptor 2 (TLR2) Cascade pathway
Innate Immune System pathway
G2/M Transition pathway
Cell Cycle, Mitotic pathway
G1 Phase pathway
Disease pathway
deletions in the AMER1 gene destabilize the destruction complex pathway
Signaling by Wnt pathway
Separation of Sister Chromatids pathway
Nuclear Envelope Reassembly pathway
MAPK targets/ Nuclear events mediated by MAP kinases pathway
ERKs are inactivated pathway
Inhibition of replication initiation of damaged DNA by RB1/E2F1 pathway
Signaling by GPCR pathway
Integration of energy metabolism pathway
Resolution of Sister Chromatid Cohesion pathway
Beta-catenin phosphorylation cascade pathway
Signaling by WNT in cancer pathway
MyD88 cascade initiated on plasma membrane pathway
ERK/MAPK targets pathway
Signaling by FGFR in disease pathway
DARPP-32 events pathway
Degradation of beta-catenin by the destruction complex pathway
Glycolysis pathway
Toll Like Receptor TLR1:TLR2 Cascade pathway
AMER1 mutants destabilize the destruction complex pathway
Cell Cycle pathway
Glucose metabolism pathway
Metabolism pathway
MAP kinase activation in TLR cascade pathway
Immune System pathway
Nonsense-Mediated Decay (NMD) pathway
PP2A-mediated dephosphorylation of key metabolic factors pathway
M Phase pathway
MASTL Facilitates Mitotic Progression pathway
Toll Like Receptor 5 (TLR5) Cascade pathway
Toll Like Receptor TLR6:TLR2 Cascade pathway
AXIN mutants destabilize the destruction complex, activating WNT signaling pathway
Cyclin D associated events in G1 pathway
T41 mutants of beta-catenin aren't phosphorylated pathway
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) pathway
Negative regulation of FGFR signaling pathway
Spry regulation of FGF signaling pathway
APC truncation mutants have impaired AXIN binding pathway
misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling pathway
RNF mutants show enhanced WNT signaling and proliferation pathway
Mitotic G2-G2/M phases pathway
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex pathway
Toll Like Receptor 9 (TLR9) Cascade pathway
disassembly of the destruction complex and recruitment of AXIN to the membrane pathway
deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling pathway
S37 mutants of beta-catenin aren't phosphorylated pathway
AXIN missense mutants destabilize the destruction complex pathway
TCF dependent signaling in response to WNT pathway
Costimulation by the CD28 family pathway
Mitotic Metaphase and Anaphase pathway
Mitotic Prometaphase pathway
Cyclin A/B1 associated events during G2/M transition pathway
G1/S Transition pathway
Toll-Like Receptors Cascades pathway
APC truncation mutants are not K63 polyubiquitinated pathway
S45 mutants of beta-catenin aren't phosphorylated pathway
MyD88 dependent cascade initiated on endosome pathway
Mitotic G1-G1/S phases pathway
misspliced GSK3beta mutants stabilize beta-catenin pathway
Glycogen storage diseases pathway
TCF7L2 mutants don't bind CTBP pathway
CTLA4 inhibitory signaling pathway
Signalling by NGF pathway
Gene Expression pathway
Adaptive Immune System pathway
truncations of AMER1 destabilize the destruction complex pathway
Activated TLR4 signalling pathway
Initiation of Nuclear Envelope Reformation pathway
NGF signalling via TRKA from the plasma membrane pathway
Opioid Signalling pathway
E2F mediated regulation of DNA replication pathway
Mitotic Prophase pathway
MyD88-independent cascade pathway
Signal Transduction pathway
truncated APC mutants destabilize the destruction complex pathway
Toll Like Receptor 7/8 (TLR7/8) Cascade pathway
MyD88:Mal cascade initiated on plasma membrane pathway
Signaling by FGFR pathway
TRIF-mediated TLR3/TLR4 signaling pathway
S33 mutants of beta-catenin aren't phosphorylated pathway
Myoclonic epilepsy of Lafora pathway
Mitotic Anaphase pathway
Metabolism of carbohydrates pathway
Nuclear Events (kinase and transcription factor activation) pathway
XAV939 inhibits tankyrase, stabilizing AXIN pathway
Toll Like Receptor 10 (TLR10) Cascade pathway
Toll Like Receptor 4 (TLR4) Cascade pathway
|
||||||||||||||||||||||
| KEGG |
TGF-beta signaling pathway pathway
Tight junction pathway
Long-term depression pathway
Oocyte meiosis pathway
Chagas disease (American trypanosomiasis) pathway
mRNA surveillance pathway pathway
Hepatitis C pathway
Tight junction pathway
TGF-beta signaling pathway pathway
Long-term depression pathway
Oocyte meiosis pathway
mRNA surveillance pathway pathway
Hepatitis C pathway
Chagas disease (American trypanosomiasis) pathway
|
||||||||||||||||||||||
| INOH | |||||||||||||||||||||||
| PID NCI |
IL8- and CXCR2-mediated signaling events
Regulation of retinoblastoma protein
ErbB1 downstream signaling
p53 pathway
C-MYC pathway
TGF-beta receptor signaling
ATR signaling pathway
PDGFR-beta signaling pathway
PLK1 signaling events
|
||||||||||||||||||||||
| Cross-References | |||||||||||||||||||||||
| SwissProt | |||||||||||||||||||||||
| TrEMBL | |||||||||||||||||||||||
| UniProt Splice Variant | |||||||||||||||||||||||
| Entrez Gene | |||||||||||||||||||||||
| UniGene | Bt.34380 | ||||||||||||||||||||||
| RefSeq | NM_181031 | ||||||||||||||||||||||
| HUGO | |||||||||||||||||||||||
| OMIM | |||||||||||||||||||||||
| CCDS | |||||||||||||||||||||||
| HPRD | |||||||||||||||||||||||
| IMGT | |||||||||||||||||||||||
| EMBL | |||||||||||||||||||||||
| GenPept | |||||||||||||||||||||||
| RNA Seq Atlas | |||||||||||||||||||||||